Subclinical heart failure post cancer chemotherapy
Unfortunately, some therapies required to cure or control the cancer are cardiotoxic. This can lead to subclinical and clinical heart failure (HF) in patients with or without underlying cardiac risk factors. Cancer therapeutics related cardiac dysfunction (CTRCD) might lead to interruption or alteration of cancer therapy. Some patients can present weeks and years after treatment. Read More...